Edward N. Libby, MD

Edward N. Libby, MD

Associate Professor, Medical Oncology Division, University of Washington School of Medicine, Associate Member, Clinical Research Division, Fred Hutch

Research Focus:
Dr. Edward N. Libby's practice and research focus are in clinical trials for patients with multiple myeloma, Waldenström macroglobulinemia and amyloidosis. Additional Resources: A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis  

years treating myeloma: 12

Number of Myeloma Patients Treated Annually: 300

Details & contact info

Seattle Cancer Care Alliance

825 Eastlake Avenue East Eastlake Capitol Hill
Seattle, Washington, United States, 98109

Phone: 855 557 - 0555

View Full Physician Bio

Send an Email


Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies